Group 1 - The National Medical Products Administration approved the listing of the innovative drug Deuteroenzalutamide capsules (brand name: Hainaanan®) developed by Haichuang Pharmaceutical, providing a new treatment option for adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after receiving abiraterone acetate and chemotherapy [1][4][6] - The approval marks a significant milestone for Haichuang Pharmaceutical, representing 12 years of innovative research and development, and is the first small molecule innovative drug approved in Chengdu Tianfu International Bio-city [2][3][4] - Deuteroenzalutamide is an androgen receptor (AR) inhibitor developed based on Haichuang's core deuterated drug platform and has received support from the National Major New Drug Creation Technology Major Project [4][6] Group 2 - Prostate cancer is the fifth most common cancer among men in China, with an increasing incidence rate. It is estimated that by 2024, there will be 160,000 new cases of mCRPC in China, rising to 176,000 by 2030 [6] - The launch of Deuteroenzalutamide fills a clinical gap as there were no approved AR inhibitors for this indication in China prior to its approval [6][11] - Haichuang Pharmaceutical plans to enhance academic promotion efforts to increase awareness of the product among doctors and patients, aiming to improve patient survival rates and quality of life [7][11] Group 3 - Chengdu Tianfu International Bio-city has established a complete biopharmaceutical ecosystem from research and development to industrialization, supporting the growth of innovative pharmaceutical companies [2][8] - The bio-city provides comprehensive lifecycle services for enterprises, including streamlined approval processes, financial and market activities, and shared facilities to reduce collaboration costs [8][10] - The bio-city has also implemented green energy solutions, such as distributed photovoltaic projects, to ensure stable energy supply for biopharmaceutical enterprises [10] Group 4 - Haichuang Pharmaceutical has six additional products in various stages of clinical trials and several in preclinical research, indicating a robust product pipeline [11] - The company emphasizes sustainable and healthy development, focusing on long-term strategic planning to benefit more patients with new drug developments [11][12] - Chengdu Tianfu International Bio-city aims to continue fostering high-level innovation and support the biopharmaceutical industry’s high-quality development through comprehensive policy guarantees and resource mobilization [12][13]

华培动力：收到新能源车企项目定点意向书 5月30日晚，华培动力（603121）发布公告称，公司近日收到国内一家新能源车企的项目定点意向书， 定点产品为热管理系统PTC水加热器，项目生命周期为5年，预计2026年开始量产，生命周期内销售金 额约900万元。 资料显示，华培动力成立于2006年6月，主营业务是涡轮增压器、传感器等关键零部件的研发、生产及 销售。 所属行业：汽车–汽车零部件–底盘与发动机系统 安图生物：产品取得医疗器械注册证 5月30日晚，安图生物（603658）发布公告称，公司及全资子公司安图实验仪器（郑州）有限公司于近 日收到国家药品监督管理局、河南省药品监督管理局颁发的医疗器械注册证。包括"巨细胞病毒IgM抗 体检测试剂盒"等产品。 资料显示，安图生物成立于1999年9月，主营业务是体外诊断试剂及仪器的研发、制造、整合及服务。 所属行业：医药生物–医疗器械–体外诊断 映翰通：调整回购股份价格上限至65.04元/股 5月30日晚，映翰通（688575）发布公告称，公司拟将回购价格上限调整为65.04元/股。此次调整旨在 保障回购方案顺利实施，除价格调整外，回购方案其他内容不变。公司已累计回购股份 ...

Market Overview - On May 30, the last trading day before the Dragon Boat Festival, the market opened lower and experienced weak fluctuations, with the North Stock 50 index rising by 0.25% while the Shanghai Composite Index fell by 0.31% to 3353.07 points [1] - The total trading volume of A-shares for the half day was 771.57 billion yuan [1] Monetary Policy - The People's Bank of China announced a 7-day reverse repurchase operation of 291.1 billion yuan at a fixed rate of 1.40%, with a net injection of 148.6 billion yuan for the day [1] Industry Developments - The China Securities Association is formulating a special evaluation method for securities companies, focusing on contributions to key areas such as technology finance, green finance, and digital finance [1] Pharmaceutical Sector Performance - The pharmaceutical sector saw significant gains, with stocks like Ruizhi Pharmaceutical and Huana Pharmaceutical hitting a 20% limit up, while other related sectors such as CRO and brain-computer interface also experienced upward trends [2] Sector Performance Data - The top performing sectors included: - Chicken: +2.55% - Innovative Drugs: +2.52% - Pork: +2.47% - Immune Therapy: +1.94% - COVID-19 Drug Concept: +1.94% [3] Investment Outlook for Innovative Drugs - The investment value of innovative drugs is viewed positively due to ongoing supportive policies, improving payment conditions, and upgrading research capabilities of supply-side enterprises [4] - Companies with strong innovation capabilities and rich product pipelines are expected to benefit in the long term from the continuous promotion of bulk purchasing of drugs and consumables [4] Company Profiles - **Huana Pharmaceutical**: A high-tech enterprise focused on the R&D, production, and sales of chemical drugs and traditional Chinese medicine, with a promising antidepressant drug ZG001 [7] - **Kexing Pharmaceutical**: An innovative biopharmaceutical company engaged in the R&D and sales of recombinant protein drugs and micro-ecological preparations, with a strong international presence [7] - **Guanhao Biological**: Actively advancing the application for a human genetic resource sample library to support innovation in drug development and health services [7] - **Haichuang Pharmaceutical**: An international innovative drug company focusing on cancer and metabolic diseases, utilizing PROTAC technology for drug development [8]

Core Viewpoint - Hecotech Pharmaceuticals has received approval for its core product, Deutetrabenazine capsules, marking the company's first commercialized product after years of operating with zero drug revenue [2][3]. Group 1: Product Approval and Market Potential - Deutetrabenazine capsules are approved for treating metastatic castration-resistant prostate cancer (mCRPC) in adult patients who have not previously received novel androgen receptor inhibitors [3]. - The drug is the first deuterated mechanism innovation in the prostate cancer field and the first domestic innovative drug approved for this indication [3]. - According to GLOBOCAN 2022, there were 1.467 million new prostate cancer cases globally in 2022, with 134,000 new cases reported in China [3]. Group 2: Company Financials and Historical Context - Prior to the approval of Deutetrabenazine, Hecotech Pharmaceuticals had maintained a "zero drug revenue" status, resulting in cumulative losses of 1.703 billion yuan from 2019 to 2024 [4]. - The company is accelerating its commercialization process and has established a GMP-compliant R&D production base in Chengdu, along with a professional marketing team [4]. Group 3: Competitive Landscape - Deutetrabenazine is a deuterated version of enzalutamide, which was originally developed by Astellas and Medivation and has generated over $4 billion in global sales by 2019 [5]. - Enzalutamide's sales reached $5.67 billion in 2024, making it a significant revenue source for Astellas [5]. - Several domestic companies have developed generic versions of enzalutamide, with competition expected to intensify as the patent expires in 2026 [5].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 近日，海创药业股份有限公司（以下简称"公司"）从国家药品监督管理 局（以下简称"NMPA"）网站查询获悉，公司自主研发的 1 类新药海纳安®（通 用名：氘恩扎鲁胺软胶囊）获得国家药监局批准上市，用于治疗接受醋酸阿比 特龙及化疗后出现疾病进展，且既往未接受新型雄激素受体抑制剂的转移性去 势抵抗性前列腺癌（mCRPC）成人患者。根据公开资料查询，氘恩扎鲁胺软胶囊 是国内第一款针对该类患者人群获得批准上市的创新药物。 现将相关情况公告如下： 证券代码：688302 证券简称：海创药业 公告编号：2025-030 海创药业股份有限公司 自愿披露关于氘恩扎鲁胺软胶囊新药上市申请 获得批准的公告 氘恩扎鲁胺软胶囊（曾用名：HC-1119 软胶囊）是公司自主研发的、用于治 疗转移性去势抵抗性前列腺癌(mCRPC)的 1 类新药，是第二代雄激素受体（AR） 抑制剂，获得国家重大新药创制科技重大专项支持。氘恩扎鲁胺（HC-1119）中 国Ⅲ期临床研究达到主要终点，数据显示，相较 ...

Group 1 - The innovative drug concept stocks are experiencing a downturn, with several companies seeing declines of over 5% [1] - Notable companies affected include Sanofi, Haisun Pharmaceutical, Huisheng Biological, Rejing Biological, Haichuang Pharmaceutical, and Ruizhi Pharmaceutical [1] - Other companies such as Saiseng Pharmaceutical and Hasan Union are also following the downward trend [1]

证券代码：688302 证券简称：海创药业 公告编号：2025-029 海创药业股份有限公司 关于召开 2025 年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 会议召开时间：2025 年 6 月 4 日（星期三）15:00-16:00 ? 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） ? 会议召开方式：上证路演中心网络文字互动 ? 投资者可于 2025 年 5 月 27 日（星期二）至 6 月 3 日（星期二） 公司邮箱 ir@hinovapharma.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 海创药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 地了解公司 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 6 月 4 日（星期三）15:00-16:00 举行 2025 年第一季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会 ...

证券代码：688302 证券简称：海创药业 公告编号：2025-029 海创药业股份有限公司 重要内容提示： 投资者可于 2025 年 5 月 27 日（星期二）至 6 月 3 日（星期二） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 ir@hinovapharma.com 进行提问。公司将在说明会上对投资 者普遍关注的问题进行回答。 海创药业股份有限公司（以下简称"公司"）已于 2025 年 4 月 26 日发布公司 2025 年第一季度报告，为便于广大投资者更全面深入 地了解公司 2025 年第一季度经营成果、财务状况，公司计划于 2025 年 6 月 4 日（星期三）15:00-16:00 举行 2025 年第一季度业绩说明 会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2025 年第一季度的经营成果及财务指标的具体情况与投资者进行互动交 会议召开时间：2025 年 6 月 4 日（星期三）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： htt ...

关于海创药业股份有限公司 2024 年度持续督导跟踪报告 中信证券股份有限公司 一、持续督导工作情况 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场检查 的工作要求。 2、保荐人已与公司签订承销及保荐协议，该协议已明确了双方在持续督导期间 的权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、对上市公司培训等方式开 展持续督导工作，并于 2025 年 4 月 21 日至 4 月 24 日对公司进行了现场检查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督导职 责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为海创 药业股份有限公司（以下简称"海创药业"或"公司"或"上市公司"）首次 公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》等相关规定，中信证券履行持续 督导职责，并出具本持续督导本年度跟踪报告。 （2）查阅公司内部审计和内控管理等内部控制制度，查阅了公司 2024 年度内 部控 ...

Group 1: 华峰化学 - Company decided to terminate the acquisition of 100% equity in Zhejiang Huafeng Synthetic Resin Co., Ltd. and Zhejiang Huafeng Thermoplastic Polyurethane Co., Ltd. due to insufficient shareholder approval [1] - The decision was made based on prudence, as the proposal did not receive more than two-thirds of the valid voting rights at the shareholders' meeting [1] - Company will continue to promote related equity injection work and strictly fulfill asset injection commitments [1] Group 2: 中荣股份 - Actual controller and chairman Huang Huanran has been placed under residential surveillance by the police [2] - Other board members and senior management are performing their duties normally, and the board of directors is operating as usual [2] - Company specializes in the research, design, production, and sales of paper printing and packaging products [2] Group 3: 密尔克卫 - Three shareholders plan to reduce their holdings by a total of up to 2% of the company's shares through block trading [3] - The reduction includes 143.63 million shares, 97.65 million shares, and 75.03 million shares, representing 0.91%, 0.62%, and 0.47% of the total share capital respectively [3] - The reduction period is from June 6, 2025, to September 5, 2025, due to personal funding needs [3] Group 4: 舒泰神 - Subsidiary Jiangsu Beijietai Biotechnology Co., Ltd. has obtained a drug production license from the Jiangsu Provincial Drug Administration [4] - The license allows for the production of therapeutic biological products, specifically for registered declaration use [4] - The license is valid until May 7, 2030, and is not expected to have a significant impact on the company's current performance [4] Group 5: 捷顺科技 - Company won the bid for the "Chongqing Beautiful Sunshine Home and other public rental housing supporting parking space operation project" [5] - The project includes four public rental housing supporting parking lots with a total of 13,335 parking spaces [5] - The minimum guaranteed revenue for the project is quoted at 40.43 million yuan per year, with a total contract amount expected to exceed 100 million yuan [5] Group 6: 综艺股份 - Company signed an investment cooperation intention agreement to acquire control of Jiangsu Jilai Microelectronics Co., Ltd. through cash capital increase or share transfer [6] - Jilai Micro primarily engages in the research, production, and sales of power semiconductor chips and devices [6] - The transaction is expected to constitute a major asset restructuring [6] Group 7: 东山精密 - Subsidiary DSBJ PTE. LTD. plans to acquire 100% equity of French GMD Group for approximately 100 million euros (about 814 million yuan) [7] - The acquisition aims to advance the company's globalization strategy and enhance its market share in the automotive parts sector [7] - The company specializes in the research, production, and sales of electronic circuit products and precision components [7] Group 8: 诺诚健华 - Company reported a net profit of 17.97 million yuan for the first quarter of 2025, a significant turnaround from a loss of 142 million yuan in the same period last year [8] - The first quarter revenue reached 381 million yuan, representing a year-on-year growth of 129.92% [8] - The company focuses on the research, production, and commercialization of innovative drugs [8] Group 9: 凯美特气 - Shareholders plan to reduce their holdings by up to 3% of the company's shares through centralized bidding and/or block trading [9] - The total number of shares to be reduced is 20.86 million [9] - The reduction is due to personal funding needs [9] Group 10: 海创药业 - Controlling shareholder plans to reduce holdings by up to 2% of the company's shares through centralized bidding and block trading [10] - The total number of shares to be reduced is 1.98 million [10] - The reduction is due to personal funding needs [10] Group 11: 高争民爆 - Controlling shareholder plans to reduce holdings by up to 3% of the company's shares through centralized bidding and block trading [11] - The total number of shares to be reduced is 828,000 [11] - The reduction is due to the company's funding needs [11] Group 12: 金埔园林 - Two shareholders plan to reduce their holdings by a total of up to 1.91% of the company's shares [12] - The reductions include 183.93 million shares and 167.73 million shares [12] - The reasons for the reductions are asset optimization and personal funding needs [12] Group 13: 掌趣科技 - The largest shareholder plans to reduce holdings by up to 1% of the company's shares through centralized bidding or block trading [13] - The total number of shares to be reduced is 27.2 million [13] - The reduction is due to personal funding needs [13] Group 14: 美凯龙 - Company announced that its director and general manager has been placed under investigation and detention by the local supervisory committee [14] - Other board members and senior management are performing their duties normally, and daily operations are unaffected [14] - The company specializes in managing and operating self-operated and franchised shopping malls [14] Group 15: 新强联 - Major shareholder plans to reduce holdings by up to 1.89% of the company's shares through centralized bidding and block trading [15] - The total number of shares to be reduced is 717,490 [15] - The reduction is due to operational needs [15] Group 16: 日月明 - Shareholder plans to reduce holdings by up to 1% of the company's shares through centralized bidding [16] - The total number of shares to be reduced is 80,000 [16] - The reduction is due to personal funding needs [16] Group 17: 同有科技 - Major shareholder and vice president plan to reduce their holdings by up to 1.53% of the company's shares [17] - The total number of shares to be reduced is 730,850 [17] - The reduction is due to personal funding needs [17] Group 18: 爱尔眼科 - Subsidiary successfully acquired 60% equity and specific debt of Shenzhen Guangsheng Digital Technology Co., Ltd. for 650 million yuan [18] - The transaction constitutes a related party transaction [18] - The acquired asset will serve as long-term medical premises for the subsidiary [18]